Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Momentum Rank : 0 (As of May. 08, 2024)

View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada Momentum Rank?

Tribute Pharmaceuticals Canada has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Tribute Pharmaceuticals Canada Momentum Rank Related Terms

Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.stellarpharma.com

Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.

Executives

John M Gregory	director, 10 percent owner
Sj Strategic Investments Llc	10 percent owner
Joan P Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory	other: Member	340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory	other: Member	340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Headlines

No Headlines